John Sourbeer
Stock Analyst at UBS
(0.88)
# 3,932
Out of 5,105 analysts
42
Total ratings
40%
Success rate
-14.44%
Average return
Main Sectors:
Stocks Rated by John Sourbeer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYRX Cryoport | Maintains: Buy | $11 → $13 | $9.40 | +32.98% | 7 | Nov 5, 2025 | |
| ILMN Illumina | Maintains: Neutral | $110 → $120 | $134.87 | -11.03% | 4 | Oct 31, 2025 | |
| WST West Pharmaceutical Services | Maintains: Buy | $320 → $355 | $267.56 | +32.68% | 5 | Oct 24, 2025 | |
| QGEN Qiagen | Maintains: Neutral | $48 → $50 | $45.22 | +10.57% | 5 | Aug 7, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Buy | $170 → $240 | $186.58 | +28.63% | 2 | Jul 25, 2025 | |
| STVN Stevanato Group | Maintains: Neutral | $24 → $24 | $20.82 | +12.87% | 2 | Mar 7, 2025 | |
| QDEL QuidelOrtho | Maintains: Neutral | $43 → $45 | $28.80 | +56.25% | 4 | Feb 13, 2025 | |
| PACB Pacific Biosciences of California | Downgrades: Neutral | $2 | $2.12 | -5.66% | 3 | Nov 11, 2024 | |
| MEDP Medpace Holdings | Maintains: Buy | $452 → $480 | $557.90 | -13.96% | 4 | Mar 8, 2024 | |
| BRKR Bruker | Maintains: Buy | $94 → $102 | $45.13 | +126.01% | 3 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $50 | $15.46 | +223.42% | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $142 → $128 | $125.46 | +2.02% | 2 | Jul 27, 2022 |
Cryoport
Nov 5, 2025
Maintains: Buy
Price Target: $11 → $13
Current: $9.40
Upside: +32.98%
Illumina
Oct 31, 2025
Maintains: Neutral
Price Target: $110 → $120
Current: $134.87
Upside: -11.03%
West Pharmaceutical Services
Oct 24, 2025
Maintains: Buy
Price Target: $320 → $355
Current: $267.56
Upside: +32.68%
Qiagen
Aug 7, 2025
Maintains: Neutral
Price Target: $48 → $50
Current: $45.22
Upside: +10.57%
ICON Public Limited Company
Jul 25, 2025
Maintains: Buy
Price Target: $170 → $240
Current: $186.58
Upside: +28.63%
Stevanato Group
Mar 7, 2025
Maintains: Neutral
Price Target: $24 → $24
Current: $20.82
Upside: +12.87%
QuidelOrtho
Feb 13, 2025
Maintains: Neutral
Price Target: $43 → $45
Current: $28.80
Upside: +56.25%
Pacific Biosciences of California
Nov 11, 2024
Downgrades: Neutral
Price Target: $2
Current: $2.12
Upside: -5.66%
Medpace Holdings
Mar 8, 2024
Maintains: Buy
Price Target: $452 → $480
Current: $557.90
Upside: -13.96%
Bruker
Mar 1, 2024
Maintains: Buy
Price Target: $94 → $102
Current: $45.13
Upside: +126.01%
Feb 2, 2023
Initiates: Neutral
Price Target: $50
Current: $15.46
Upside: +223.42%
Jul 27, 2022
Maintains: Buy
Price Target: $142 → $128
Current: $125.46
Upside: +2.02%